Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Is Expanding Transparency Efforts To Focus On Industry Questions

This article was originally published in The Pink Sheet Daily

Executive Summary

Sharfstein said the agency has split up its transparency efforts into three groups, adding one dedicated to explaining its inner workings to regulated industry.

You may also be interested in...



Transparency Phase III: FDA Offers Designs For Industry Review

Transparency Phase III: FDA Offers Designs For Industry Review

Where's Your Application? FDA May Soon Have An App For That

Agency's transparency initiative may include a tracking system similar to Health Canada's so that reviewers can avoid having to field phone calls from sponsors asking about the status of an application.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS068746

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel